{"id":"al2846-capsules","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target of AL2846 has not been widely disclosed in public literature, it is being developed by Chia Tai Tianqing Pharmaceutical Group as an oncology therapeutic in Phase 3 clinical trials. The drug is designed to inhibit aberrant signaling pathways that drive malignant cell growth.","oneSentence":"AL2846 is a small-molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:32.046Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oncology indication (specific tumor type not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT06860971","phase":"PHASE3","title":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-18","conditions":"Thyroid Cancer","enrollment":144},{"nctId":"NCT05745363","phase":"PHASE1, PHASE2","title":"Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02-24","conditions":"Differentiated Thyroid Cancer","enrollment":33},{"nctId":"NCT05815862","phase":"PHASE2","title":"Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02-15","conditions":"Advanced Lung Cancer, Ovarian Cancer","enrollment":29},{"nctId":"NCT05922345","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06-08","conditions":"Non-small Cell Lung Cancer","enrollment":518},{"nctId":"NCT05011019","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-09-07","conditions":"Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors","enrollment":22},{"nctId":"NCT06278493","phase":"PHASE1, PHASE2","title":"A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2018-08-23","conditions":"Pancreatic Cancer","enrollment":34},{"nctId":"NCT06116240","phase":"PHASE1","title":"A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-09-02","conditions":"Solid Tumor","enrollment":135},{"nctId":"NCT04325776","phase":"PHASE2","title":"A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-09-24","conditions":"Bone Metastatic Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04337879","phase":"PHASE1, PHASE2","title":"A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-07-20","conditions":"Advanced Colorectal Cancer","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AL2846 capsules","genericName":"AL2846 capsules","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL2846 is a small-molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival. Used for Oncology indication (specific tumor type not publicly confirmed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}